Pre-clinical studies and clinical trials using combinations of VEGF-A blocking and Ang-2 inhibitors (peptide-Fc fusion “peptibody”), as well as bispecific CrossMab anti-VEGF/anti-Ang-2 Ab (RG7716) (Figure 3), are presently ongoing to estimate their efficacy in tumor and ocular neovascularization [147,148,165,167]. This evidence concerns the gene VEGFA and neoplasm.